The Gulf conflict has disrupted global supply chains, pushed...
REITs have changed the way commercial real estate is owned a...
What really powers the cloud? Behind every Google search, A...
What really powers the cloud? Behind every Google search, A...
Luxury real estate is one of the most talked-about segments ...
Metropolis Healthcare plans to expand its presence to 1,000 towns across India over the next three years from the current 750, while adding around 2,500 collection centres. The diagnostic chain also plans to increase its centre-to-lab ratio from 24 to 35 and raise company-owned centres from 750 to 1,000. The company is targeting annual organic revenue growth of 14-15 per cent and an EBITDA margin of 28 per cent, compared with 24.5 per cent currently. It is also investing in technology, genomics, mini-hubs and acquisitions as it seeks to expand its organised market presence.
Metropolis Healthcare plans to widen its geographical presence across India as part of its next phase of growth, with the diagnostic chain targeting 1,000 towns over the next three years compared with its current reach of 750 towns.
As part of its expansion plan, the company will focus on improving infrastructure utilisation by increasing the number of collection centres linked to each laboratory. Metropolis currently operates 24 collection centres for every laboratory and plans to raise this to 35 centres per laboratory over the next two to three years.
Ameera Shah, Executive Chairperson of Metropolis Healthcare, said the Indian diagnostics industry is valued at around USD 11 billion and is growing at about 11 per cent annually. She noted that around 85 per cent of the market is still unorganised.
Metropolis, which began building a network of standardised diagnostic centres about 25 years ago, currently operates 209 laboratories and more than 5,000 centres across India and five African countries. The company ended FY26 with revenue of INR 1,646 crore.
The company plans to add around 2,500 collection centres to its existing network. Of its more than 5,000 centres, around 750 are company-owned and are mainly located in major cities including Mumbai, Pune, Chennai and Bengaluru. Metropolis plans to increase its company-owned centres to 1,000.
Between FY24 and FY26, the company recorded a 12 per cent increase in patient volume, while test volumes grew 13 per cent. Shah said the organised segment, which currently represents around 15 per cent of the diagnostics market, is expected to expand considerably by 2034, creating further scope for organised players.
Managing Director Surendran Chemmakotil said the company’s focus over the next three years would be on technology, science-led branding and profitable growth. Metropolis is already using artificial intelligence in non-science processes to improve productivity, workflows and turnaround times, and plans to increasingly operate as a technology-led company.
The company is also looking to broaden the services available at its centres. It plans to convert some locations into mini-hubs offering basic radiology services along with pathology. Around 100 such hubs are planned over the next three years.
Metropolis is targeting an increase in its EBITDA margin from 24.5 per cent currently to 28 per cent over the next three years. The improvement is expected to come from operating leverage, better asset utilisation and vendor consolidation.
The company recorded a 17.6 per cent compound annual growth rate in revenue over the past three years and is targeting organic revenue growth of 14-15 per cent annually, excluding acquisitions. Chemmakotil said the higher centre-to-lab ratio and greater adoption of specialised testing through its TruHealth bundles should improve revenue per customer. Automation is also expected to limit the need for manpower additions in line with volume growth and support margins.
Specialised testing, particularly genomics, is another area of focus. Metropolis has established a genomics centre of excellence in Gurugram and another centre in Mumbai, using Illumina NovaSeq technology.
Chemmakotil said genomics is seeing growing demand and the company is working with specialised clinicians to encourage its use as a primary diagnostic tool for cancer, neurological disorders and prenatal testing.
Metropolis also continues to explore acquisitions and has integrated 25 acquisitions so far. Its future M&A strategy will focus on filling geographical gaps, acquiring distressed assets that can be improved through its operational capabilities and gaining specialised skill sets from healthcare startups.
On pricing, Shah said accuracy and precision remain important considerations in diagnostics despite the high price sensitivity of the Indian market. She pointed out that India has one of the world's most competitive and cost-effective diagnostic markets, with 60-70 tests available for around USD 10-15. However, she said private-sector customers are primarily looking for better quality and service, particularly because diagnostic errors can have serious consequences in cases such as cancer.
Source PTI
17th Nov, 2026
17th Nov, 2026
17th Nov, 2026
17th Nov, 2026
17th Nov, 2026